Cat. No. |
Product Name |
Information |
PC-42823 |
Erlotinib mesylate
|
Erlotinib (CP-358774. |
PC-42822 |
Erlotinib hydrochloride
|
Erlotinib (CP-358774. |
PC-42819 |
WZ-3146
|
WZ-3146 is a potent, mutant-selective EGFR kinase inhibitor with IC50 of 2, 2, 5, 14 and 66 nM for EGFRL858R, EGFRL858R/T790M, EGFRE746-A750, EGFRE746-A750/T790M and wt EGFR, respectively, suppresses the growth of EGFR T790M containing cell lines and inhibit EGFR phosphorylation.. |
PC-63158 |
AZ5104
|
AZ 5104 is the active metabolite of AZD 9291 (Osimertinib), is an irreversible inhibitor of EGFR-sensitizing and T790M resistance mutations (IC50=15-17 nM) that spares the wild-type form of the receptor (IC50=480 nM). |
PC-62999 |
BIBU1361 dihydrochloride
|
BIBU1361 is a potent, selective, orally active EGFR inhibitor with IC50 of 3 nM, shows weak activity against HER2 (IC50=280 nM) and no inhibition on IGF1R, HGFR, Src, and VEGFR2 (IC50>10 uM). |
PC-62998 |
BIBU1361
|
BIBU1361 is a potent, selective, orally active EGFR inhibitor with IC50 of 3 nM, shows weak activity against HER2 (IC50=280 nM) and no inhibition on IGF1R, HGFR, Src, and VEGFR2 (IC50>10 uM). |
PC-62304 |
HER2-IN-3
|
HER2-IN-3 is a type I HER2 inhibitor that has a similar profile to HER2-IN-2. |
PC-62303 |
HER2-IN-2
|
HER2-IN-2 is a potent, selective HER2 inhibitor, only shows potent inhibition for EGFR and Abl in a panel of kinases. |
PC-62121 |
Theliatinib
|
Theliatinib (HMPL 309) is a highly selective, potent, ATP-competitive inhibitor of EGFR with IC50 of 3 nM/22 nM for EGFR/EGFRT790M/L858R mutant, respectively. |
PC-61769 |
SKLB188
|
SKLB188 is a novel multikinase inhibitor and potently inhibits EGFR with IC50 of 5 nM. |
PC-60919 |
GNS-1481
|
A novel potent, irreversible, T790M mutant-selective inhibitor of mutant EGFR with IC50 of 6.2, 3.4 and 4.2 nM for L858R-T790M, T790M and Del19-T790M, respectively. |
PC-60918 |
GNS-1486
|
A novel potent, irreversible, T790M mutant-selective inhibitor of mutant EGFR with IC50 of 8.3, 4.2 and 4.3 nM for L858R-T790M, T790M and Del19-T790M, respectively. |